By Karen Roman
Aktis Oncology said it appointed Dr. Ken Herrmann to the Board of Directors.
Dr. Herrmann specializes in nuclear medicine and has over a decade of experience in clinical investigation, the company said.
“Ken’s joining us on the Board is timely, given the ongoing clinical assessment of our first-in-class Nectin-4-targeted radioconjugate,” said Matthew Roden, PhD, Aktis Oncology’s President and CEO.
Dr. Herrmann currently serves as the Chair of Aktis’ Scientific Advisory Board (SAB) and acts as Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen in Germany, it stated. To date, he has authored over 700 peer-reviewed publications, the company said.
“My experience from leading Aktis’ SAB has afforded me the deep understanding of the groundbreaking work we do here and I am eager to further advance our novel alpha-emitting radiopharmaceuticals in this new role on the Board of Directors,” said Dr. Herrmann.
Contact:
